Triple Receptor Agonist (GLP-1 / GIP / Glucagon) | Weight Loss & Metabolic Research Peptide | For Research Use Only

Retatrutide is a cutting-edge investigational peptide that acts as a triple agonist of the GLP-1, GIP, and glucagon receptors. This synergy provides an unparalleled approach to weight loss, appetite suppression, and glycaemic regulation. Early research shows that Retatrutide significantly outperforms other incretin mimetics like Semaglutide and Tirzepatide in terms of fat loss and metabolic efficiency.

The 20mg format is ideal for precise titration in both short-term and long-term obesity and diabetes research models.

🔍 Key Features

• Triple Mechanism: GLP-1, GIP & Glucagon Receptor Agonism

• Suppresses Appetite & Cravings

• Stimulates Fat Oxidation & Increases Energy Expenditure

• Improves Insulin Sensitivity & Glycaemic Control

• Ideal for Obesity, Type 2 Diabetes & Metabolic Syndrome Research

• Long Half-Life Suitable for Weekly Protocols

⚙️ Compound Details

• Compound Name: Retatrutide

• CAS Number: 2381089-83-2

• Molecular Formula: C₂₀₉H₃₂₉N₅₅O₆₆

• Molecular Weight: ~4717.35 g/mol

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised powder

• Unit Size: 20mg per vial

🧊 Storage & Handling

• Storage (lyophilised): –20°C in a dark, moisture-free environment

• Reconstitution: Use 1–2ml sterile bacteriostatic water

• Post-Reconstitution: Store at 2–8°C; use within 10–14 days

• Avoid: Heat, direct sunlight, and repeated freeze-thaw cycles

⚠️ For Research Use Only

Retatrutide – 20mg is provided exclusively for laboratory and scientific research. It is not intended for human use, medical treatment, or diagnosis.